|
Synonyms: ASLAN-004 | ASLAN004 | CSL 334 | CSL-334
Compound class:
Antibody
Comment: The INN eblasakimab refers to a fully human, IgG4κ monoclonal antibody whose target is interleukin-13 receptor subunit α1 (IL13RA1). Eblasakimab represents a first-in-class agent against IL13Rα1. Blocking IL13Rα1 function is predicted to inhibit signalling by the pro-inflammatory cytokines IL-4 and IL-13.
The peptide sequences for the heavy and light chains in eblasakimab's INN record are claimed in patent WO2008060813A2 (Merck and CSL Behring) [2], and these map to the antibody identified as 10G5-6 therein. Interrogation of CSL Behring's pipeline webpage suggests that eblasakimab may be their anti-IL13Rα1 lead candidate ASLAN004, that is being developed for the treatment of allergic disorders such as atopic dermatitis and asthma. As of October 2021 ASLAN004 was licensed to ASLAN Pharmaceuticals. Further online investigation indicates that ASLAN004 was formerly known as CSL 334. Other than the associated patent, there is no clearly identifiable published information to verify the eblasakimab-ASLAN004 association. Our prediction is made in good faith, based on information in the public realm. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Phase 1 studies of ASLAN004 have been undertaken. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03721263 | Study of ASLAN004 in Healthy Subjects | Phase 1 Interventional | Aslan Pharmaceuticals | ||
| NCT04090229 | A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis | Phase 1 Interventional | Aslan Pharmaceuticals | ||
